Ninth Circuit Revives DOJ Subpoena for Transgender Healthcare Patient Records in Federal Investigation

On August 14, 2026, a divided federal appeals court revived a Department of Justice subpoena demanding patient and personnel records from a Washington-based telehealth clinic that provides gender-affirming care. The 2-1 decision by the Ninth Circuit Court of Appeals marks the first time an appellate court has upheld one of the more than two dozen administrative subpoenas the DOJ issued to clinics and hospitals nationwide in the summer of 2025.

The ruling reverses a lower court decision that had blocked the subpoena against the clinic, QueerDoc, on the grounds that it was issued in bad faith. By reinstating the demand, the Ninth Circuit has established a binding precedent across its jurisdiction—which includes California and several other western states—affirming that the executive branch can direct its investigative powers toward its broader policy objectives.[1][2][5]

The legal mechanism driving the DOJ's investigation relies on a specific intersection of federal healthcare laws. The department issued the subpoena under the Health Insurance Portability and Accountability Act (HIPAA), which contains a provision authorizing federal investigators to demand medical records when probing potential healthcare offenses. Specifically, the DOJ claims it is investigating potential violations of the Federal Food, Drug, and Cosmetic Act (FDCA).

The inquiry focuses on whether the off-label prescription of puberty blockers and cross-sex hormones to minors constitutes "misbranding" or healthcare fraud. While off-label prescribing—using an FDA-approved drug for an unapproved indication—is a common and legal practice in medicine, the DOJ asserts it has the authority to investigate whether clinics or drug manufacturers are falsely promoting these treatments.[2][4][6]

When QueerDoc initially challenged the subpoena, U.S. District Judge Jamal Whitehead in Seattle quashed the demand. Whitehead concluded that the DOJ was not conducting a genuine fraud investigation, but was instead using its subpoena power for the "improper purpose" of executing the administration's stated policy goal of eliminating gender-affirming care. The Ninth Circuit majority, however, rejected that premise.

Writing for the court, Judge Carlos T. Bea, joined by Judge Daniel Bress, ruled that a president's political motives do not invalidate a legally structured investigation. "The President may direct DOJ to exercise its statutory authority in a manner that aligns with his broader policy goals," Bea wrote, adding that the goal of ending such care is not inherently an improper objective for the executive branch.[1][2][3]

The majority opinion also waded into the medical debate surrounding the treatments, characterizing the long-term risks and efficacy of puberty blockers and cross-sex hormones as "uncertain." The court noted that the administration is "entitled to adopt a position on either side of this 'ongoing debate among medical experts.'"

This framing underscores a broader judicial deference to the executive branch's ability to set law enforcement priorities, even when those priorities target highly contested social and medical issues. By separating the administration's political rhetoric from the statutory validity of the HIPAA subpoena, the Ninth Circuit effectively cleared the way for the DOJ to continue its probes within the circuit's boundaries.[1][3][5]

The ruling drew a sharp dissent from Judge Richard A. Paez, who argued that the lower court was entirely justified in blocking the subpoena. Paez wrote that there is "a mountain of evidence" indicating the DOJ is using the threat of criminal investigation as a pretext to pressure healthcare providers into halting gender-affirming care.

Patient advocacy groups and legal organizations supporting QueerDoc have echoed this concern, arguing that the subpoenas are designed to bypass the legislative process by making the legal and financial risks of providing care too high for clinics to bear. They warn that forcing providers to hand over sensitive files—including billing data and patient records—weaponizes federal investigative tools against marginalized groups.[3][4][6]

Despite the DOJ's appellate victory, QueerDoc is not immediately required to turn over its records. The Ninth Circuit panel sent the case back to the district court to evaluate the clinic's remaining legal objections. Judge Whitehead must now determine whether the subpoena is overly broad, whether it imposes an undue administrative burden on the small telehealth practice, and whether compliance would violate fundamental patient privacy rights.

The appellate judges explicitly noted that the lower court could consider protective orders or other mechanisms to shield the identities of the patients involved, leaving a narrow pathway for the clinic to protect its medical files.[1][7]

The Ninth Circuit's decision represents a critical juncture in a nationwide legal battle that is playing out across multiple jurisdictions. Similar DOJ subpoenas issued to hospitals in other states have faced fierce resistance, with legal challenges currently pending before the First, Third, Fourth, and Fifth Circuit Courts of Appeals.

If these appellate courts reach conflicting conclusions regarding the legality or scope of the DOJ's civil subpoenas, it could create a circuit split. Such a division would likely prompt the Supreme Court to intervene, setting up a landmark showdown over the limits of executive investigative power, off-label prescribing rights, and the privacy of transgender patients.[4][5][7]

Legal analysts observing the case note that courts traditionally grant the executive branch wide latitude in conducting investigations, requiring a very high burden of proof to quash a subpoena for bad faith. However, the sheer volume of identical subpoenas issued to gender-affirming care clinics nationwide has tested the limits of that deference. As the district court prepares to review the privacy implications of the QueerDoc subpoena, healthcare providers across the Ninth Circuit are bracing for increased federal scrutiny of their prescribing practices.[5][7]